Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus

Dexa Medica

Status and phase

Completed

Phase 4

Conditions

Type 2 Diabetes Mellitus

Treatments

Drug: placebo tablet of DLBS1033

Drug: DLBS1033

Study type

Interventional

Funder types

Industry

Identifiers

NCT01865474

DLBS1033-0212

Details and patient eligibility

About

This is a prospective, double-blind, randomized, and controlled study. The investigational product, DLBS1033 at a dose of 490 mg thrice daily or placebo, will be given for an 8-week course of therapy.

DLBS1033 effectively demonstrated fibrinolytic, fibrinogenolytic as well as antithrombotic activities. Hypercoagulation state with high fibrinogen level is usually found in diabetes mellitus patients.

Therefore, the hypothesis of interest of this study is that DLBS1033 will reduce fibrinogen level of diabetes mellitus patients better than that of the Control Group.

Full description

There will be 2 groups of treatment, each consisting of 68 subjects, with the treatment regimens as the following:

Treatment I : DLBS1033 bioactive fraction tablet @ 490 mg, three times daily. Treatment II : Placebo tablet of DLBS1033, three times daily.

Clinical examination to evaluate the efficacy of the investigational drug will be performed at baseline and every follow-up visit (at interval of 4 weeks) over the 8 weeks of study period. All subjects will be advised to follow such a lifestyle modification throughout the study period.

All subjects will be under direct supervision of a medical doctor during the study period.

During the study period, anti-diabetes treatment taken by study subjects should still be continued. Other treatment related to subjects' concomitant illnesses, such as hypertension, and/or dyslipidemia, is allowed during subjects' participation in the study.

Other medication such as anti-platelets, fibrinolytic agents and anti-coagulants, or other treatment including herbals/alternatives which may affect haemostatic system, are not allowed to be used during the study period.

Enrollment

122 patients

Sex

All

Ages

25 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosed as type 2 diabetes mellitus with A1c > 7.0% at Screening.
Men or women, between 25-65 years of age.
Have been being treated with lifestyle intervention and/or any oral anti-diabetic agents and/or insulin.
Adequate liver function: ALT and AST ≤ 2.5 times upper limit of normal.
Adequate renal function: serum creatinine < 2.0 times upper limit of normal.
Able to take oral medication.

Exclusion criteria

For females of childbearing potential: Pregnancy, breast-feeding, the intention of becoming pregnant.
- Patients must accept pregnancy tests during the trial if menstrual cycle is missed.
- Fertile patients must use a reliable and effective contraceptive.
The presence of clinically significant electrocardiographic abnormality
History of acute coronary syndrome (myocardial infarction, stroke, unstable angina pectoris), peripheral arterial diseases, venous thromboembolism or other cardiovascular events.
History of other arteriosclerotic disease necessitating medical or pharmacological treatment.
Severe hypertension (systolic blood pressure ≥ 180 mm Hg, diastolic ≥ 110 mm Hg).
Treatment with antiplatelets or antithrombotic agents, including other oral lumbrokinase products within 14 days prior to Screening.
Subjects with prior experience with DLBS1033.
Subjects with high-risk of bleeding
Presence of malignancies as observed clinically or by anamnesis.
Subjects with any other disease state, including chronic or acute systemic infections, or uncontrolled illnesses, which judged by the investigator, could interfere with trial participation or trial evaluation.
Subjects with known or suspected allergy to study medication or similar products.
Subjects with concurrent herbal (alternative) medicines or food supplements suspected to have effect on the primary efficacy endpoint.
Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to Screening.